SFA-002

Name: SFA-002
Brand: SFA Therapeutics, Inc.

Oral, once-daily deuterated short-chain fatty acid tablet for plaque psoriasis (mild-to-severe), currently in Phase 2 clinical development.

Compare products Visit websiteClaim or join

What is SFA-002?

Oral, once-daily deuterated short-chain fatty acid tablet for plaque psoriasis (mild-to-severe), currently in Phase 2 clinical development. Investigational therapy not approved by the FDA.

Product typeDrug Discovery & Biotech

Pricing ·

Deployment

APINot available

What teams use SFA-002 for

Immune tolerance therapy for plaque psoriasis

Combination therapy for pancreatic cancer

Therapy for chronic liver disease to hepatocellular carcinoma

Therapies for rheumatoid arthritis and inflammatory bowel disease

Integrations and access

Platforms, integrations, and language support vary by plan and region. Confirm final requirements with the vendor.

Platforms

IntegrationsAPI and webhooks

Languages

Support

What reviewers say

Community reviewsReviews are owned and editable by their authors.

Loading community reviews…

Enterprise readiness

Compliance claims are normalized from current vendor documentation and independently reviewed by SOTA2.

Data retention:

Benchmarks and comparisons

Independent benchmarksStructured task results are being verified.

Side-by-side comparisonsComparison workspaces will be available in a later release.

Alternatives to SFA-002

IntegrationsPre-built connectivity to every instrument, historian, ELN/LIMS, and enterprise data store that matters in bioprocess.0.00 reviewsDrug Discovery & Biotech

Numerion Labs Drug Discovery PlatformAI-driven drug-hunting superplatform that uses a universal chemistry foundation model (COSMOS), a hyper-scalable enumerator (APEX), and expert optimization algorithms (EXPO) to...0.00 reviewsDrug Discovery & Biotech

EnablementFrom data foundation to decisions.0.00 reviewsDrug Discovery & Biotech